Midterm Outcomes of Angioplasty for Pediatric Renovascular Hypertension

PurposeTo evaluate the midterm outcomes of percutaneous transluminal renal angioplasty (PTRA) for pediatric renovascular hypertension (RVH).Materials and MethodsThe clinical data of patients who underwent PTRA for RVH in the authors’ hospital from 2012 to 2019 were retrospectively analyzed. Postprocedural blood pressure, glomerular filtration rate (GFR) of the affected kidney, restenosis, and complications were closely monitored.ResultsPTRA was performed in a total of 30 children (20 boys and 10 girls), with a mean age of 7.3 years ± 0.7 (range, 40 days to 13.9 years) and a mean weight of 25.0 kg ± 2.3 (range, 3.4–53 kg). The median follow-up period was 26.5 months (range, 1 month to 7.5 years). Technical success was achieved in 26 (86.7%) of the 30 patients. Restenosis developed in 3 patients (10.0%). Only 1 patient underwent stent implantation, and the stent fractured 8 months later, requiring further intervention. There were no other complications. In terms of clinical benefit of blood pressure control after the initial PTRA procedure, 15 patients (50%) were cured and 7 patients (23.3%) showed improvement. There was no significant difference in the etiology, lesion location, and lesion length between patients with clinical benefit and failure (P = .06, P = .202, and P = .06, respectively). GFR of the affected kidney was significantly improved from 19.9 mL/min ± 11.2 to 38.1 mL/min ± 11.9 at the 6-month follow-up after PTRA (P < .001).ConclusionsThe overall results of PTRA for pediatric RVH caused by different etiologies are promising. PTRA not only provided a clinical benefit of blood pressure control in 73.3% of the patients but also significantly improved the function of the affected kidney.     

小型移动数字成像系统下行经皮冠状动脉腔内成形术

目的 :探讨移动数字成像系统GE OECSeries 980 0进行经皮冠状动脉腔内成形术 (PTCA)的可行性和安全性。方法 :回顾分析 32例应用GE OECSeries 980 0X线机进行PTCA治疗冠心病的临床资料。结果 :①本组病例成功率为 90 6 % (2 9/ 32 ) ,血管成功率为 88 1% (37/ 4 2 ) ,病变成功率 83% (39/ 4 7)。成功病例狭窄由术前目测平均直径狭窄(92 8± 3 5 ) %减少到术后的 (6 5± 4 2 ) %。②AMI溶栓后补救性PTCA成功率高。结论 :应用GE OECSeries 980 0X线机能够满足心血管病区心脏介入治疗的需要 ,是安全可行的和具有良好的成本 效益比     

Effect of Shuxinyin (舒心饮) on In-Stent Restenosis after Coronary Artery Stenting

Objective: To evaluate the effect of anti-platelet regimens and it's combination with Shuxinyin (SXY, 舒心饮,) on in-stent restenosis after stent implantation. Methods: Forty-four patients with successful stent implantation in a coronary artery were randomly assigned to the treated group (n=20) and the control group (n=24). The treated group received: SXY and anti-platelet therapy. The control group were treated with anti-platelet regimens only. Platelet activation was assessed before and immediately after the stenting by flow cytometry, the expression of P-selectin (CD62P) and glycoprotein(GP) Ⅱb/Ⅲa receptor. It was reassessed on the 30th day after stenting. Plasma fibrinogen (Fg) and C-reaction protein (CRP) were measured by biuret and laser scattering turbidimetry respectively at the same time. Observation was made on the scoring of the symptoms of Qi deficiency syndrome, Qi-Yin deficiency syndrome and blood stasis syndrome in the two groups. Differences between groups were compared. Results: Compared with the control group, combination with SXY and anti-platelet therapy was remarkable in reducing plasma CRP (P<0.05), and also with the tendency to decrease plasma Fg, GPⅡb/Ⅲa and CD62P. It could also evidently decrease the scoring of Qi-Yin deficiency syndrome, Qi deficiency syndrome and blood stasis syndrome after stenting (P<0.05, 0.01, 0.01) respectively. Follow-up survey found 40% relapse of angina pectoris with 4 cases of in-stent restenosis proved by angiography in the treated group. But the relapse of angina pectoris in the control group was 67% with 2 cases of myocardial infarction (MI), 7 cases of in-stent restenosis proved by angiography and one death. Conclusions: Combination with SXY and anti-platelet regimens can prevent stent thrombosis and in-stent restenosis after stent implantation, and it seems superior to anti-platelet therapy only.     

血管内支架成形术治疗症状性椎动脉起始部狭窄的疗效分析

目的研究血管内支架成形术治疗症状性椎动脉起始部狭窄的安全性及有效性。方法对16例症状性椎动脉起始部狭窄的患者行支架成形术治疗。16例患者均成功植入球囊扩张支架。结果术后11例患者恢复正常管径;5例患者狭窄程度明显改善,残余狭窄均小于20%。无1例发生严重并发症。在6个月的临床随访中,16例患者均无脑缺血发作及再狭窄发生。结论血管内支架成形术是治疗症状性椎动脉起始部狭窄的安全、有效方法,其长期疗效还需进一步随访研究。     

介入疗法在急性肢体动脉闭塞治疗中的应用价值

目的探讨介入疗法在急性肢体动脉闭塞治疗中的应用价值。方法回顾性总结28例急性肢体动脉闭塞介入治疗经验。采用经皮血管腔内成形术和动脉内溶栓术治疗上肢动脉闭塞5例、腹主动脉下段闭塞1例、下肢动脉闭塞22例。结果经术后4个月~9年临床观察,急性单段动脉闭塞血管再通率为100%(8/8例)、多段动脉闭塞血管再通率为80%(16/20例),总血管再通率为85.71%(24/28例)。结论介入疗法是治疗急性肢体动脉闭塞的一种有效方法,值得推广应用。     

Prevention of Restenosis after Coronary Angioplasty with Low-Density Lipoprotein Apheresis

Abstract: A prospective study was performed to determine whether low-density lipoprotein (LDL) apheresis, when performed only immediately before and after percutaneous transluminal coronary angioplasty (PTCA), is effective in preventing restenosis of coronary artery lesions following PTCA. Thirty-six patients with coronary heart disease (CHD) and hypercholesterolemia were divided into 2 groups. The 9 patients in the LDL group underwent LDL-apheresis 1 day before and 5 days after PTCA while the 27 patients of the control group underwent PTCA but did not undergo LDL-apheresis. Follow-up coronary angiography (CAG) was performed 4 months after PTCA. The rate of restenosis of coronary artery lesions was significantly lower in the LDL group (0%) than in the control group (30%). These findings suggest that LDL-apheresis, when performed before and after PTCA, is effective in preventing restenosis of coronary artery lesions in patients with CHD and hypercholesterolemia.     

Cardiovascular Laser Application

With the invention of the laser, many clinical disciplines have taken advantage of this new energy source. Its precision, intensity and energy density is superior to all other known surgical devices. Based on the principle of light amplification from a photon-emitting resonator, the monochromaticity, collimation and coherence provide the high-energy density of the laser beam for medical applications. The state-of-the-art and future potential of laser use in cardiovascular diseases will be reviewed. Most of the work in this field has been accomplished during the past decade with numerous research projects. Although many technical advances have been made, so far the results in cardiovascular medicine are in the areas of vessel anastomosis, ablation of conduction passes for arrhythmia therapy, and angioplasty. In this paper, special attention will be given to the recent success in XeCl excimer laser application for photodecomposition of tissue with a goal of improved recanalization. The high-power density of the XeCl excimer laser provides significant advantages for the disruption of both embolic and calcified plaque. Regardless of the type of tissue ablated, gross, histologic, and ultra-structural analysis confirmed the absence of thermal injury in luminar recanalization as well as in animal studies. Progress in the manufacture of catheters, with multiple very small diameter fibers, led to the decisive breakthrough in clinical laser angioplasty. Peripheral as well as coronary arteries have been successfully recanalized followed by balloon dilatation. The ease of application and the success achieved thus far have resulted in an optimistic assessment for laser medicine.